

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?): 2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAplus - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:32:05 ON 20 DEC 2005

Page 2

=> file reg COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:32:12 ON 20 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6
DICTIONARY FILE UPDATES: 19 DEC 2005 HIGHEST RN 870234-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10723140\Struc 1.str

The chemical structure consists of a central cyclohexane ring (atoms 1-6) fused with a cyclopentane ring (atoms 7-11). Attached to the cyclohexane ring are a phenyl group (Ph), a methyl group (Me), and a methylene group (CH2). Attached to the cyclopentane ring are two hydroxyl groups (OH), a methyl group (Me), and a methylene group (CH2). There are also several ethyl groups (CH3) and a carbonyl group (C=O).

chain nodes :
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
ring nodes :
1 2 3 4 5
chain bonds :

Page 3

2-13 3-12 4-6 5-14 6-7 7-8 8-9 8-15 9-10 10-11 12-16 16-17 17-18 18-19
19-20 20-21 21-22 21-23 23-24 24-25 24-26

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 2-13 3-4 4-5 5-14 8-15 21-22 21-23 23-24

exact bonds :

3-12 4-6 6-7 7-8 8-9 9-10 10-11 12-16 16-17 17-18 18-19 19-20 20-21
24-25 24-26

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS
26:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 12:32:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 46 TO ITERATE

100.0% PROCESSED 46 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 514 TO 1326
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> l2 full
FULL SEARCH INITIATED 12:32:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1025 TO ITERATE

100.0% PROCESSED 1025 ITERATIONS
 SEARCH TIME: 00.00.01

9 ANSWERS

L3 9 SEA SSS FUL L1

=> file caplus medline

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
161.33	161.54

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:32:45 ON 20 DEC 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:32:45 ON 20 DEC 2005

=> l3

L4 1063 L3

=> dup rem 14

PROCESSING COMPLETED FOR L4

L5 863 DUP REM L4 (200 DUPLICATES REMOVED)

=> l5 and PY<1991

L6 1 L5 AND PY<1991

=> d 16 ibib abs hitstr

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1990:605515 CAPLUS
 DOCUMENT NUMBER: 113:205515
 TITLE: Preparation and use of prostaglandin derivatives for
 the treatment of glaucoma or ocular hypertension
 INVENTOR(S): Stjernschantz, Johan W.; Resul, Bahram
 PATENT ASSIGNEE(S): Pharmacia AB, Swed.
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9002553	A1	19900322	WO 1989-SE475	19890906 <--
W: AU, DK, FI, JP, NO, US				
AU 8941898	A1	19900402	AU 1989-41898	19890906 <--
AU 625096	B2	19920702		
EP 364417	A1	19900418	EP 1989-850294	19890906 <--
EP 364417	B1	19940209		
EP 364417	B2	20040414		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 03501025	T2	19910307	JP 1989-509228	19890906
JP 2721414	B2	19980304		
EP 569046	A1	19931110	EP 1993-109514	19890906
EP 569046	B1	20021113		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 101342	E	19940215	AT 1989-850294	19890906
ES 2062102	T3	19941216	ES 1989-850294	19890906
EP 1225168	A2	20020724	EP 2002-9255	19890906
EP 1225168	A3	20030326		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				

EP 1224934	A2	20020724	EP 2002-9256	19890906
EP 1224934	A3	20030326		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 1224935	A2	20020724	EP 2002-9257	19890906
EP 1224935	A3	20030326		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 227576	E	20021115	AT 1993-109514	19890906
EP 1300149	A2	20030409	EP 2003-516	19890906
EP 1300149	A3	20030514		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 1300150	A2	20030409	EP 2003-517	19890906
EP 1300150	A3	20030514		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 1300151	A2	20030409	EP 2003-518	19890906
EP 1300151	A3	20030514		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ES 2186670	T3	20030516	ES 1993-109514	19890906
EP 1348437	A2	20031001	EP 2003-14533	19890906
EP 1348437	A3	20031119		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1339132	A1	19970729	CA 1989-611003	19890912
DK 9001121	A	19900504	DK 1990-1121	19900504 <--
DK 175842	B1	20050329		
FI 92690	B	19940915	FI 1990-2258	19900504
FI 92690	C	19941227		
US 5296504	A	19940322	US 1992-987520	19921208
US 5321128	A	19940614	US 1992-988389	19921208
US 5422368	A	19950606	US 1992-986943	19921208
US 5422369	A	19950606	US 1994-202409	19940225
US 5578618	A	19961126	US 1995-390394	19950216
US 5849791	A	19981215	US 1995-461334	19950605
US 5627208	A	19970506	US 1995-470607	19950606
JP 08109132	A2	19960430	JP 1995-241200	19950920
JP 2955213	B2	19991004		
JP 10081624	A2	19980331	JP 1997-209419	19970804
JP 3612178	B2	20050119		
US 6030999	A	20000229	US 1999-307814	19990510
US 6187813	B1	20010213	US 1999-307813	19990510
US 6429226	B1	20020806	US 2000-562447	20000501
US 2001014693	A1	20010816	US 2001-781896	20010212
US 6417230	B2	20020709		
US 2002173525	A1	20021121	US 2002-106228	20020327
US 2003166729	A1	20030904	US 2002-288732	20021105
US 2003181493	A1	20030925	US 2002-330846	20021227
US 2004167190	A1	20040826	US 2003-723140	20031125
DK 200401645	A5	20041027	DK 2004-1645	20041027
PRIORITY APPLN. INFO.:			SE 1988-3110	A 19880906
			SE 1988-3855	A 19881028
			SE 1988-3111	A 19880906
			EP 1989-850294	A 19890906
			EP 1993-109514	A3 19890906
			EP 2002-9256	A3 19890906
			EP 2003-516	A3 19890906
			JP 1995-241200	A3 19890906
			WO 1989-SE475	A 19890906
			US 1990-469442	B1 19900410
			DK 1990-1121	A 19900504
			US 1991-740371	B1 19910724
			US 1992-986943	A3 19921208
			US 1992-988389	A1 19921208
			US 1995-461341	A1 19950605
			US 1999-307813	A1 19990510
			US 2001-781896	A1 20010212

US 2002-106228 A1 20020327
 US 2002-330846 B1 20021227

OTHER SOURCE(S): MARPAT 113:205515
 AB Ophthalmol. compns. for topical treatment of glaucoma or ocular hypertension comprise, in an ophthalmol. compatible carrier, an effective amount of a derivative of PGA, PGB, PGD, PGE, or PGF having an ω -chain C13BC14DR2 [B is a single, double, or triple bond between C13 and C14; D = (un)substituted C1-10 chain optionally interrupted by O, S, or N; R2 = (un)substituted ring]. Thus, crude 15-(R,S)-17-phenyl-18,19,20-trinor-PGF 2α (preparation given) was esterified and purified by column chromatog. to give 15-(R)-17-phenyl-18,19,20-trinor-PGF 2α isopropyl ester (I) in 46% yield. I (10 μ g) reduced intraocular pressure in healthy human volunteers to 11.2 mm Hg 8 h after administration (control = 15.1 mm Hg at 8 h). I and other prepared prostaglandin derivs. all significantly reduced intraocular pressure without significant irritating effect (ocular discomfort); 2 of the derivs. caused little, if any, conjunctival/episcleral hyperemia in man.

IT 130209-82-4P


RL: PREP (Preparation)
 (preparation of, for glaucoma treatment)

RN 130209-82-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



=> 15 and PY<1992

L7 2 L5 AND PY<1992

=> d ti 1-2

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

TI PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

TI Preparation and use of prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

=> d ibib abs hitstr 1

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:626256 CAPLUS

DOCUMENT NUMBER: 117:226256

TITLE: PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor

AUTHOR(S): dynamics in healthy volunteers
 Alm, Albert; Villumsen, Joergen
 CORPORATE SOURCE: Dep. Ophthalmol., Univ. Hosp., Umea, S-901 85, Swed.
 SOURCE: Archives of Ophthalmology (Chicago, IL, United States)
 (1991), 109(11), 1564-8
 CODEN: AROPAW; ISSN: 0003-9950

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The prostaglandin analog PhXA34 was tested in two studies in normal human eyes; 1, 3, and 10 µg of PhXA34 reduced the intraocular pressure by about 2, 3, and 4 mm Hg, resp., 6 to 10 h after a single topical dose. The only side effect observed was a slight conjunctival hyperemia after 10 µg of PhXA34. In a second study we determined the effect of 10 µg of PhXA34 once daily for 7 days on intraocular pressure, outflow facility, aqueous flow, blood-aqueous barrier permeability, ocular discomfort, and hyperemia. The mean intraocular pressure wa below 9 mm Hg 12 h post dose. About one third of the intraocular pressure reduction could be explained by increased outflow facility. Aqueous flow was unaffected. Treatment caused a 21% increase in aqueous fluorescence 1 h after an oral dose of fluorescein. Mild ocular discomfort and some hyperemia were initially observed in half of the subjects, but frequency and magnitude of these side effects declined during the study.

IT 130209-82-4, PhXA 34

RL: BIOL (Biological study)


(as ocular hypotensive, aqueous humor dynamics response to, in humans, antiglaucoma activity in relation to)

RN 130209-82-4 CAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



=> stjernschantz
 L8 2 STJERN SCHANTZ

=> resul
 L9 122 RESUL

=> 18 and 19
 L10 0 L8 AND L9

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	25.73	187.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

Page 8

CA SUBSCRIBER PRICE ENTRY SESSION
 -1.46 -1.46

STN INTERNATIONAL LOGOFF AT 12:43:28 ON 20 DEC 2005